Clinical Trial Detail

NCT ID NCT03674814
Title Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors University of Chicago
Indications

prostate cancer

Therapies

Enzalutamide + Relacorilant

Age Groups: adult senior

No variant requirements are available.